A recent randomized controlled trial, utilizing RNA-sequencing and immunohistochemical analysis data from NSCLC tumor samples, has provided evidence of the antitumor effect of combining immunotherapy with chemotherapy in advanced NSCLC patients with high PD-L1 expression [50]. This evidence concerns the gene CD274 and non-small cell lung carcinoma.